WO2000041671A9 - Composition, dispositif, et methode pour retirer des matieres adipeuses sous cutanees - Google Patents

Composition, dispositif, et methode pour retirer des matieres adipeuses sous cutanees

Info

Publication number
WO2000041671A9
WO2000041671A9 PCT/US1999/029374 US9929374W WO0041671A9 WO 2000041671 A9 WO2000041671 A9 WO 2000041671A9 US 9929374 W US9929374 W US 9929374W WO 0041671 A9 WO0041671 A9 WO 0041671A9
Authority
WO
WIPO (PCT)
Prior art keywords
skin
perfluorocarbon
composition
area
group
Prior art date
Application number
PCT/US1999/029374
Other languages
English (en)
Other versions
WO2000041671A3 (fr
WO2000041671A2 (fr
Inventor
Nikolai Tankovich
Original Assignee
T & T Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by T & T Pharmaceuticals Ltd filed Critical T & T Pharmaceuticals Ltd
Publication of WO2000041671A2 publication Critical patent/WO2000041671A2/fr
Publication of WO2000041671A3 publication Critical patent/WO2000041671A3/fr
Publication of WO2000041671A9 publication Critical patent/WO2000041671A9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/69—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine
    • A61K8/70—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine containing perfluoro groups, e.g. perfluoroethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/89—Suction aspects of liposuction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/84—Drainage tubes; Aspiration tips
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0468—Liquids non-physiological
    • A61M2202/0476—Oxygenated solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/08—Lipoids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/05—General characteristics of the apparatus combined with other kinds of therapy
    • A61M2205/058—General characteristics of the apparatus combined with other kinds of therapy with ultrasound therapy

Definitions

  • This invention relates to a composition of matter, device, and method for dissolving fat associated with or near the skin
  • the composition is directed to perfluorocarbon compositions, the devices incorporate perfluorocarbons for topical application to the skin, and methods involve either subdermal injection or topical application of perfluorocarbon compositions
  • a major concern relating to human skin is the accumulation of excess layers of fat cells, especially in middle age and elderly people, which causes them to appear fatty and older
  • Nerves are also affected by the traumatic aspects of the procedure, causing loss of feeling in the treated area for some months afterwards.
  • compositions of perfluorocarbons which overcomes these problems and inefficiencies of subcutaneous fat removal, is directed to compositions of perfluorocarbons and methods of using these compositions for subcutaneous fat removal.
  • the advantage provided by the compositions and method of the invention is based on the ability of perfluorocarbons to rapidly emulsify the fat in the adipose cells without the necessity of a cannula or other blunt or sharp instrument to mechanically break, tear, or otherwise disconnect the adipose cells from site of interest.
  • Emulsification of the fat in the adipose tissue obviates the use of a cannula or other blunt or sharp instrument to mechanically break, tear or otherwise disconnect the adipose cells from the site of interest.
  • emulsified fat is easily drawn out of the body by suction without the trauma caused by the presently available techniques of liposuction.
  • the invention is directed to a composition comprising perfluorocarbon and one or more agents selected from the group consisting of anesthetics and vasoconstrictors.
  • the composition is in association with a pharmaceutical carrier. It is an object of the invention to provide a composition for use in techniques, in particular liposuction techniques, for removal of tissue and fat from a patient.
  • Another aspect of the invention is a method for subcutaneous removal of lipid or fat cells from a patient.
  • the method comprises the steps of contacting subcutaneous lipid or fat cells in an area of the patient with an effective or sufficient amount of the composition of the invention for a sufficient period of time to emulgate the lipid or fat cells into an emulsion.
  • the emulsion is removed in a subsequent step.
  • a version of the method involves oscillating the lipid or fat cells which were contacted with the composition with a sufficient amount of oscillation energy to enhance emulgation of the fat compared to emulgation without oscillation.
  • Another object of the invention is to provide a method of removal of fat from a patient with no damage or minimal damage to blood vessels.
  • Figure 1 is a diagram of a section of skin.
  • Figure 2 is a block diagram of the tissue layers of skin.
  • Figure 3 illustrates skin fat liposuction using perfluorocarbons and an oscillator.
  • Figure 4 shows transdermal delivery systems.
  • Figure 5 shows examples of drug release or drug diffusion mechanisms that describe devices and systems used in the present invention to deliver perflurocarbons from polymers to give various release profiles.
  • PFCs perfluorocarbons
  • emulgate means to form an emulsion.
  • tumescent technique means a technique for liposuction which involves the infiltration of a “tumescent solution.”
  • a tumescent solution contains a local anesthetic agent, e.g. lidocaine, and a vasoconstrictor, e.g. epinephrine, in a pharmaceutical carrier which is infiltrated into the subcutaneous fat typically in a liposuction surgical procedure through a cannula or through a needle, in some procedures with the aid of a peristaltic pump.
  • the vasoconstrictor and local anesthetic agent of the tumescent solution respectively, reduce bleeding and eliminate the need for general anesthetics.
  • Figure 1 is a cross section of human skin showing the location of fat and blood vessels.
  • Figure 1 illustrates epidermis, dermis and subcutaneous fat with the hair shaft 33 of a hair growing in a hair duct 31 from dermal papilla 32. Also shown is a nerve ending 34, a sweat gland 35, a sebaceous gland 38 , arteries 36, and veins 37.
  • Subcutaneous fat or lipid is predominated with adipocytes, i.e. fat cells which contain cytoplasmic lipids.
  • the subcutaneous fat is both a cushion to prevent mechanical injury as well as a storage depot for high-potency energy sources.
  • Fat is stored in adipocytes, which are enormously distended cells that comprise the majority of cells in adult adipose tissue.
  • the composition and method of the invention provide an effective amount of perfluorocarbon which, in contact with the adipocytes and, in due course, in contact with the fat within the adipocytes at the site of interest, emulgages the fat stored in the adipocytes.
  • Adipocytes are arranged in sheet-like lobules separated by thin, fibrous septa in which blood vessels supply nutrients. These septa anchor the deepest limits of the reticular dermis to underlying fascia, with an intervening cushion of subcutaneous lobules formed by masses of adipocytes.
  • the blood vessel-rich septa are ripped, broken and otherwise traumatized by conventional liposuction techniques using conventional tumescent solutions.
  • the present invention provides a composition for use in the removal of tissue and fat from a patient.
  • the composition comprises a perfluorocarbon (PFC) and one or more agents selected from the group consisting of anesthetics and vasoconstrictors.
  • PFC perfluorocarbon
  • the composition can be combined with a pharmaceutical carrier, preferably a pharmaceutical carrier suitable for cosmetic or aesthetic surgical procedures, in particular liposuction, for removal of body fat.
  • a pharmaceutical carrier preferably a pharmaceutical carrier suitable for cosmetic or aesthetic surgical procedures, in particular liposuction, for removal of body fat.
  • Compositions used in the art for such procedures as known as "tumescent solutions.”
  • the PFC of the composition is selected from one or more of the group of PFCs consisting of one or more aliphatic straight-chain and branched fluoroalkanes, mono-or bicyclic and optionally fluoralkly-substituted flurocycloalkanes, perfluorinated aliphatic or bicyclic amines, bis(perfluoroalkl) ethenes; or alternatively from one or more substituted and unsubstituted alkyl, alkenyl, alkynyl, alkoxyl groups which can have straight or branched chains, ring structures including single or fused ring structures, e.g. phenyl, or naphthyl.
  • the unsaturated groups can have a single site of unsaturation or a plurality of sites of unsaturation.
  • Fluorocarbon compositions such as Perftoran and perflubron are included. Medically useful PFCs and syntheses thereof are disclosed in U.S. Patent Nos.
  • the composition of the invention provides a tumescent solution.
  • the amount of PFC in the composition is in the range from about 0.1% to about 100% w/v, preferably in the range from about 10% to about 70%. A particularly preferred range is from about 50% to about 65%.
  • Pharmaceutical carriers, particularly for cosmetic surgical procedures are well known in the art, and include but are not restricted to solutions, emulsions, transferosomes (Krantz and Carr, Textbook of Pharmacological Principals of Medical Practice, (1964), pp. 26-32; Lippold, B.C. Pharmacy International (1980) 3: 1-60; Gregoriadis, G. and Neerunjun, D.E., Liposomes and Their Uses in Biology and Medicine (1977), pp. 14-16.
  • Vasoconstrictors which are useful in the composition of the invention include but are not restricted to epinephrine, levarterenol, phenylephrine, athyladrianol, ephedrine.
  • Anesthetics which are useful in the composition of the invention include but are not restricted to lidocaine, marcaine, nesacaine, diprivan, novocaine, ketalar, xylocaine.
  • a preferred tumescent solution is a composition which comprises the PFC Perftoran lm , a vasoconstrictor, and an anesthetic.
  • Perftoran is obtained from Pharmpreparaty Company, Russia.
  • Perftoran contains 12 mEq of sodium carbonate per liter, 15.2 % perfluorodecalin, 7.6%> perfluoromethylcyclohexypiperidin, 4% Proxanol-268, 0.039% potassium chloride, 0.6%) sodium chloride, 0.019%> magnesium chloride, 0.028 % calcium chloride, 0.13%> sodium hydrocarbonate, 0.02%> sodium hydrophosphate, 0.2% glucose, the remainder being water.
  • the preferred tumescent solution is a mixture of 5% by volume 2% lidocaine (total 0.1% in solution), 1% epinephrine, and Perfotoran.
  • the tumescent solution is directed into the site of interest where lipids need to be extracted.
  • METHOD OF THE INVENTION in another aspect, is directed to a method for subcutaneous removal of lipid from a patient The method comprises the step of contacting the subcutaneous lipid with an effective or sufficient amount of a composition comprising PFC for a sufficient period of time to emulgage the lipid into an emulsion.
  • Another step involves removing the emulsion from the patient
  • a preferred version of the method involves administering oscillation to the lipid after the PFC is in contact with the lipid for a sufficient period of time. A sufficient amount of oscillation is administered to speed up or enhance emulgation so that more emulsion is formed than without oscillation.
  • the method involves contacting the lipid with a composition of PFC, preferably a composition of PFC in a pharmaceutical carrier.
  • a composition of PFC preferably a composition of PFC in a pharmaceutical carrier.
  • the amount of PFC in the composition is in the range of about 50% to about 80%
  • the composition of PFC further comprises one or more agents selected from the group consisting of anesthetics and vasoconstrictors, and preferably in association with a pharmaceutical carrier to form a tumescent solution.
  • agents selected from the group consisting of anesthetics and vasoconstrictors and preferably in association with a pharmaceutical carrier to form a tumescent solution.
  • the amount of PFC in the composition as well as amounts of vasoconstrictor and local anesthetic are as described above for the compositions of the invention.
  • An ultrasonic transducer (UST) (6) applies oscillation to the SCF or lipid in the adipocytes.
  • the step of removing the emulsion can be achieved by aspirating with a cannula or needle (8)
  • the steps of contacting and removing comprise the well known surgical procedure of liposuction
  • oscillations i.e. the mechanical vibrations of high frequency are topically applied to promote emulgation, i.e. to enhance the process of the fat molecules binding to the PFC and emulsification, i.e., dissolving of fat molecules.
  • the suspension or emulsion is sucked out without blood vessel damage, a major advantage of the invention.
  • Ultrasonic instruments and methods for applying oscillation to the lipid in a patient in an area of concern are known in the an, as disclosed in U.S. Patent Nos. 5,419,761 and 4,886,491; and in M. Zocchi, Clin. Plast. Surg. (1996) pp. 575-598.
  • Transferosome Compositions of Perfluorocarbons Another aspect of the invention is directed to a transferosome composition which comprises transferosomes which comprise one or more perfluorocarbons (PFCs).
  • Transferosomes are lipid vesicles which have the unique property, unlike conventional lipid suspensions (such as standard liposomes or mixed lipid micelles) of being sufficiently flexible or deformable to pass through pores or other biological apertures which are appreciably smaller than the size of the transferosome (G. Cevc et al., Biochimica et Biophysica Acta 1368:201-215, 1998). Tranferosomes provide the advantage of maximizing, relative to conventional liposomes, the transdermal delivery of a therapeutic agent. Accordingly, an objective of the invention involves providing a composition suitable for topical application to the skin, the composition for transporting therapeutic amounts of perfluorocarbon to the hypodermis to thereby contact and emulgate subcutaneous fat deposits therein.
  • SPC soybean phosphatidylcholine
  • Transferosomes are prepared by mixing an ethanolic SPC solution with the appropriate amount of an edge-active molecule, such as sodium cholate.
  • an edge-active molecule such as sodium cholate.
  • Other biocompatible surfactants could be used in different suspensions (G. Cevc, 1991, European Patent 91 114 163.8-2114).
  • the suspension is subsequently mixed with triethanolamine-HCL buffer to yield total lipid concentration of 10 wt%.
  • the resulting suspension is sonicated, frozen and thawed (2-3 times) and brought to the desired size (as measured by means of photon correlation spectroscopy) by ultrasonication or intermediate-pressure homogenization.
  • Vesicle suspension is ultimately sterilized by filtration through a 0.2 micron porous filter (Poretics, CA). The final vesicle size is confirmed by dynamic light scattering. Further guidance for preparing transfersomal compositions is provided in G.
  • Cevc Lipid properties as a basis for the modeling and design of liposome membranes, in G. Gregoriadis, Ed., Liposome Technology, 2nd ed., CRC -Press, Boca Raton, FL, 1992, pp. 1-36; and in G. Cevc, Material Transport across permeability barriers by means of lipid vesicles in: R. Lipowsky (ed.), Handbook of Physics of Biological Systems, vol. I, Elsevier Science, Chap. 9, 1995, pp. 441-466. A variety of transferosome compositions are described in detail in G. Cevc, 1991, European Patent 91 1 14 163.8-2114).
  • PFCs used in the present invention are illustrated, but not limited to those in U.S. Patent Nos. 5,455,373; 5,637,318; and 5,679,459 which are incorporated by reference. It is understood that the PFC of the composition is selected from one or more of the group of PFCs consisting of one or more aliphatic straight-chain and branched fluoroalkanes, mono-or bicyclic and optionally fluoralkly-substituted flurocycloalkanes, perfluorinated aliphatic or bicyclic amines, bis(perfluoroalkl) ethenes; or alternatively from one or more substituted and unsubstituted alkyl, alkenyl, alkynyl, alkoxyl groups which can have straight or branched chains, ring structures including single or fused ring structures, e.g. phenyl, or naphthyl.
  • the unsaturated groups can have a single site of unsaturation or
  • a starting perfluorocarbon solution which is Perftoran contains approximately of 12 mEq of sodium carbonate per liter, 15.2 % perfluorodecalin, 7.6% perfluoromethylcyclohexypiperidin,4%) Proxanol-268, 0.039% potassium chloride, 0.6% sodium chloride, 0.019% magnesium chloride, 0.028 % calcium chloride, 0.13% sodium hydrocarbonate, 0.02%> sodium hydrophosphate, 0.2% glucose, the remainder being water.
  • 82 ml of the starting solution is mixed, for example, with 0.9 g of SPC and approx.
  • transdermal delivery system essentially means any type of a substrate, formulation, or composition that contains a substance that allows a drug or therapeutic agent (e.g. molecular agent or vesicle containing said agent) to transit from the outside of the skin through the various skin layers and into a target subcutaneous area or finally into the circulatory system to exert a pharmacological action .
  • a drug or therapeutic agent e.g. molecular agent or vesicle containing said agent
  • Transdermal delivery systems used in the present invention and guidance for combining the transfersome composition comprising PFC of the present invention with transdermal delivery systems are disclosed in detail in generally available references, including Topical Drug B oeqinvalence, and Penetration (eds Vinod
  • compositions of the invention in the methods of the invention for removing subcutaneously located fat deposits by applying the compositions in an amorphous form or in the form of a patch to an area of skin for a sufficient period of time to deliver a sufficient amount of PFC to the fat deposits beneath the amplication to emulgate the fat deposits.
  • Transdermal delivery systems used in the compositions, methods, and devices of the invention range in design from amorphous ointments to solid-state laminates or patches.
  • Many transdermal products have reached the marketplace in the world to date (Shah et al., ibid, Table III, p. 31)
  • Categories of solid state laminates or patches include "membrane-controlled,” “reservoir”, “matrix,” or “monolithic” types (Shah et al., ibid, pp. 32-33; Schaefer et al., ibid, pp. 214-215).
  • a reservoir is considered a storage place for the drug.
  • the reservoir can be in a polymeric "matrix," in a
  • Peripheral adhesive laminate structure e g Nitro TDS (Several companies), Nitrodisc (Searle), Nitro-Dur I (Key), Prostep (Lederle
  • Solid-state laminate structure e.g Transderm-Scop V (Ciba), Catapres-
  • the present invention is not limited to the above mentioned designs of transdermal systems as new approaches and combinations of each design are possible In combination with PFCs, all of these systems, however, deliver PFCs to the skin surface so that the PFC migrates through the skin to subcutaneous locations of fat deposits
  • the basic designs and relative advantages and disadvantages are well known to those skilled in the art to allow a transdermal system designer to incorporate the most suitable PFC release mechanism for the application required, and to establish efficacy of the transdermal delivery system using methods well known in the art
  • the transdermal products of the present invention achieve the objective of delivering into the subcutaneous area below the application of the transdermal product an effective amount of perfluorocarbon into subcutaneous fat deposit locations to emulgate said fat deposits
  • FIG. 5 shows examples of drug release or drug diffusion mechanisms that describe devices and systems used in the present invention to deliver PFC from polymers to give various release profiles. The invention is not limited to these six mechanism shown in Figure 5. These mechanisms serve as a guide for the system designer in formulating transdermal delivery systems of the present invention.
  • the invention includes methods for removing subcutaneously located fat deposits.
  • the method involves the step of applying a composition comprising perfluorocarbon to an area of skin for a sufficient period of time to deliver a sufficient amount of said perfluorocarbon to the fat deposits beneath the application in order to emulgate the fat deposits.
  • compositions of perfluorocarbons involve use of perfluocarbon compositions as described above, namely, a transferosome composition comprising perfluorocarbon (PFC-Transferosome), or a PFC-Transferosome composition in combination with a transdermal delivery systems described above.
  • a transferosome composition comprising perfluorocarbon PFC-Transferosome
  • PFC-Transferosome composition PFC-Transferosome composition in combination with a transdermal delivery systems described above.
  • Another composition of perfluorocarbon that is useful in the method involves liposomal or other vesicular compositions of PFCs which are well known in the art (M.G. Madzhidov et al., Perfluorocarbon Active Media and Emulsions for
  • the invention is also directed to variations on the method of applying a composition of perfluorocarbon to an area of the skin
  • the variations are directed to the step of applying
  • the step of applying comprises treating an area of the skin, preliminary to applying the composition of perfluorocarbon to that area
  • the preliminary step involves treating the skin with a physical agent to increase the permeability of the skin barrier in that area of skin to perfluorocarbon
  • These physical approaches for skin penetration enhancement include, but are not limited to, exfoliation (i e. stripping off exterior layer of the stratum cernuum) and depilation Methods for exfoliation are described in Topical Drug Bioavailablity,
  • Exfoliation in the method of the invention is also accomplished by treating the skin with laser (For example, see U.S Patent Nos 5,423,803 - Skin Surface Peeling
  • a membrane a thin connective tissue/cell monolayer membrane is effectively transparent for molecules up to molecular weight of 10,000 to 15,000
  • the drug which in the present invention is perfluorocarbon or a composition comprising perfluorocarbon, easily diffuses through the membrane into subcutaneous fat deposits located proximate the hair matrix
  • Examples 1 Application of PFC to an area of skin in the form of an amorphous ointment or cream or lotion or viscous disperson or emulsion or microemulsion or coacervate drops or microspheres or microseed involves a topical deposition of 2 - 3 ml of the composition per 100 cm 2 of the skin, massaging and rubbing in during 1 - 2 minutes until the mixture is absorbed by the skin.
  • Topical compositions of PFC as disclosed herein are readily absorbed by the skin surface in large quantities by normal skin as described above.
  • the step of skin exfoliation or depilation enhances and increasing the quantity of PFC deposited to the subdermal (i.e. subcutaneous) fat through the skin.
  • the application must be performed once a day as a minimum. For better effect, the application could be performed 2- 4 times a day.
  • patches comprising PFC are made in forms suitable for transdermal delivery of PFC for a defined time ranging from about one day to about one month.
  • a version of the claimed method is directed to the step of applying in which applying comprises a step of exfoliating an area of skin prior to applying PFC to the area of skin.
  • a well known method of exfoliation comprises treatment of an area of skin with an Erbium: YAG laser, although the method of the invention is not limited to this form of laser treatment.
  • Erbium: YAG laser treatment known as Naturalase treatment, is provided by the Advanced laser laser.
  • a version of the claimed method is directed to the step of applying in which applying comprises a step of depilating an area of skin prior to applying PFC to the area of skin.
  • Depilation typically involves skin waxing or hair plucking, although other methods of depilation are available, such as laser depilation.
  • the hair waxing process is a preferred embodiment, and involves waxing the area of skin with Azulene Wax consisting of colofodium, parafin, glycerine, parafinum liquidum, BHT, Guai-azulene, CI 75810 and made by "HAIRAWAY' company Melted wax is applied to the skin which has been cleaned with 70% isopropyl alcohol The liquid wax is covered by 4 x 4 cotton gauze After the wax becomes cold and solid, the gauze is removed against the hair growth The residue of the wax left on the skin is removed by multiple touch/removed procedure with the same gauze with wax After that the PFC composition or PFC patch or the mixture is topically applied
  • compositions, methods, and devices of the invention chemical and physical approaches in combination with PFCs are used to lower the stratum cernuum barrier properties and enhance transdermal permeation of PFCs
  • Such chemicals are used in the composition or devices of the invention in combination with PFC to increase permeability of the skin to PFC.
  • such chemicals are used to treat an area of skin preliminary to the application of PFC to the area of skin.
  • enhancers in the form of various vehicles find use in modifying the penetrability of the stratum cernuum
  • a topical formulation or device When a topical formulation or device is applied to skin, it may produce several effects on the stratum cernuum which will modify the permeability characteristics of the stratum cernuum toward any included drug, such as perfluorocarbon
  • the present invention incorporates any of the following common vehicles in combination with perfluorocarbons' transdermal patch, occlusive dressing, lipophilic substances, absorption base, emulsifying base, water-in-oil emulsion, oil-in- water emulsion, humectant, and powder (Ibid, Chapter 14).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une composition particulière, un dispositif et une méthode permettant de dissoudre des matières adipeuses associées à la peau, ou situées près de la peau. Cette composition concerne des compositions perfluorocarbonées, les dispositifs comprennent des perfluorocarbones pour une application topique sur la peau, et les méthodes comprennent l'injection sous-cutanée ou l'application topique de compositions perfluorocarbonées.
PCT/US1999/029374 1999-01-12 1999-12-09 Composition, dispositif, et methode pour retirer des matieres adipeuses sous cutanees WO2000041671A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23170599A 1999-01-12 1999-01-12
US09/231,705 1999-01-12

Publications (3)

Publication Number Publication Date
WO2000041671A2 WO2000041671A2 (fr) 2000-07-20
WO2000041671A3 WO2000041671A3 (fr) 2000-11-23
WO2000041671A9 true WO2000041671A9 (fr) 2002-04-11

Family

ID=22870339

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/029374 WO2000041671A2 (fr) 1999-01-12 1999-12-09 Composition, dispositif, et methode pour retirer des matieres adipeuses sous cutanees

Country Status (1)

Country Link
WO (1) WO2000041671A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2610022A1 (fr) 2005-06-06 2006-12-14 Georgetown University Compositions et procedes de lipomodelage
US10980925B1 (en) 2008-10-14 2021-04-20 A Hoyos Llc High definition liposculpture
US9888933B1 (en) * 2008-10-14 2018-02-13 Alfredo Ernesto Hoyos Ariza Vaser assisted high definition liposculpture
FR2937554B1 (fr) * 2008-10-27 2010-11-12 Yves Crassas Solutions salines aqueuses pour la destruction de tissus graisseux
USD883767S1 (en) 2018-10-10 2020-05-12 A Hoyos Llc Handle

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US5846516A (en) * 1992-06-03 1998-12-08 Alliance Pharmaceutial Corp. Perfluoroalkylated amphiphilic phosphorus compounds: preparation and biomedical applications
DE4221268C2 (de) * 1992-06-26 1997-06-12 Lancaster Group Ag Verwendung eines Dermatikums zur Unterstützung des Sauerstofftransportes in der Haut
US5455373A (en) * 1994-02-28 1995-10-03 Exfluor Research Corporation Method of producing perfluorocarbon halides
US5763423A (en) * 1996-01-04 1998-06-09 Clarion Pharmaeuticals Inc. Pharmaceutical compositions, novel uses, and novel form of tocopherylphosphocholine

Also Published As

Publication number Publication date
WO2000041671A3 (fr) 2000-11-23
WO2000041671A2 (fr) 2000-07-20

Similar Documents

Publication Publication Date Title
US6302863B1 (en) Method for removal of lipids via a perfluorocarbon tumescent solution
Touitou Drug delivery across the skin
Lener et al. Topical anesthetic agents in dermatologic surgery a review
Barry Novel mechanisms and devices to enable successful transdermal drug delivery
Prausnitz et al. Skin barrier and transdermal drug delivery
Ali et al. The structure of skin and transdermal drug delivery system-a review
US6030374A (en) Ultrasound enhancement of percutaneous drug absorption
US20060222695A1 (en) Deoxycholic acid liposome-based dermatological topical preparation
CA2872279C (fr) Compositions topiques de traitement de lipolyse et methodes
Nounou et al. Liposomal formulation for dermal and transdermal drug delivery: past, present and future
JP2007538010A (ja) フィコトキシンの経皮投与
Dragicevic et al. Invasomes: Vesicles for enhanced skin delivery of drugs
US20220313606A1 (en) Lipid vesicle compositions with penetration enhancing agents
US20060127429A1 (en) Topical numbing composition for laser therapy
EP2435032A1 (fr) Trousse d'administration topique ou transdermique
Kassem et al. Vesicular Nanocarriers: a potential platform for dermal and transdermal drug delivery
Barry Penetration enhancer classification
WO2000041671A9 (fr) Composition, dispositif, et methode pour retirer des matieres adipeuses sous cutanees
Atkinson et al. Targets in dermal and transdermal delivery and classification of penetration enhancement methods
Calpena Campmany et al. Technological, biopharmaceutical and pharmacokinetic advances: new formulations of application on the skin and oral mucosa
Wang et al. Improved dermal delivery of FITC–BSA using a combination of passive and active methods
CN107595766B (zh) 一种利多卡因微乳凝胶及其制备方法
Gupta et al. Penetration enhancers: Role in transdermal drug delivery system
KR20200097907A (ko) 혼합 향수성 제제를 이용한 카페인 컴플렉스 수용액과 경피흡수 펩티드(r6)를 함께 함유한 셀룰라이트 개선 화장품 조성물
Freeman et al. Topical anaesthesia of the skin: a review

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): BR CA CN IL JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): BR CA CN IL JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C2

Designated state(s): BR CA CN IL JP

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGES 4/5-5/5, DRAWINGS, REPLACED BY NEW PAGES 4/5-5/5; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

122 Ep: pct application non-entry in european phase